Because PD‐L1 expression is one of the main factors influencing the efficacy of PD‐1/PD‐L1 inhibitors, patients with esophageal cancer are often treated with PD‐L1/PD‐L1 inhibitors according to their PD‐L1 status. The gene discussed is CD274; the disease is esophageal cancer.